Literature DB >> 21995438

Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme.

Tushar K Maiti1, Michelle Permaul, David A Boudreaux, Christina Mahanic, Sarah Mauney, Chittaranjan Das.   

Abstract

Ubiquitin carboxy-terminal hydrolase L5 (UCHL5) is a proteasome-associated deubiquitinating enzyme, which, along with RPN11 and USP14, is known to carry out deubiquitination on proteasome. As a member of the ubiquitin carboxy-terminal hydrolase (UCH) family, UCHL5 is unusual because, unlike UCHL1 and UCHL3, it can process polyubiquitin chain. However, it does so only when it is bound to the proteasome; in its free form, it is capable of releasing only relatively small leaving groups from the C-terminus of ubiquitin. Such a behavior might suggest at least two catalytically distinct forms of the enzyme, an apo form incapable of chain processing activity, and a proteasome-induced activated form capable of cleaving polyubiquitin chain. Through the crystal structure analysis of two truncated constructs representing the catalytic domain (UCH domain) of this enzyme, we were able to visualize a state of this enzyme that we interpret as its inactive form, because the catalytic cysteine appears to be in an unproductive orientation. While this work was in progress, the structure of a different construct representing the UCH domain was reported; however, in that work the structure reported was that of an inactive mutant [catalytic Cys to Ala; Nishio K et al. (2009) Biochem Biophys Res Commun 390, 855-860], which precluded the observation that we are reporting here. Additionally, our structures reveal conformationally dynamic parts of the enzyme that may play a role in the structural transition to the more active form.
© 2011 The Authors Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21995438      PMCID: PMC3336103          DOI: 10.1111/j.1742-4658.2011.08393.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  38 in total

1.  Structural basis for the specificity of ubiquitin C-terminal hydrolases.

Authors:  S C Johnston; S M Riddle; R E Cohen; C P Hill
Journal:  EMBO J       Date:  1999-07-15       Impact factor: 11.598

Review 2.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

3.  A C-H triplebond O hydrogen bond stabilized polypeptide chain reversal motif at the C terminus of helices in proteins.

Authors:  M Madan Babu; S Kumar Singh; P Balaram
Journal:  J Mol Biol       Date:  2002-09-27       Impact factor: 5.469

4.  Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast.

Authors:  Miranda Stone; Rasmus Hartmann-Petersen; Michael Seeger; Dawadschargal Bech-Otschir; Mairi Wallace; Colin Gordon
Journal:  J Mol Biol       Date:  2004-11-26       Impact factor: 5.469

5.  Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.

Authors:  Chittaranjan Das; Quyen Q Hoang; Cheryl A Kreinbring; Sarah J Luchansky; Robin K Meray; Soumya S Ray; Peter T Lansbury; Dagmar Ringe; Gregory A Petsko
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

6.  hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37.

Authors:  Xiao-Bo Qiu; Song-Ying Ouyang; Chao-Jun Li; Shiying Miao; Linfang Wang; Alfred L Goldberg
Journal:  EMBO J       Date:  2006-11-30       Impact factor: 11.598

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  (His)C epsilon-H...O=C < hydrogen bond in the active sites of serine hydrolases.

Authors:  Z S Derewenda; U Derewenda; P M Kobos
Journal:  J Mol Biol       Date:  1994-08-05       Impact factor: 5.469

Review 9.  Recognition and processing of ubiquitin-protein conjugates by the proteasome.

Authors:  Daniel Finley
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

10.  The SWISS-MODEL Repository and associated resources.

Authors:  Florian Kiefer; Konstantin Arnold; Michael Künzli; Lorenza Bordoli; Torsten Schwede
Journal:  Nucleic Acids Res       Date:  2008-10-18       Impact factor: 16.971

View more
  21 in total

Review 1.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

2.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Authors:  Ze Tian; Padraig D'Arcy; Xin Wang; Arghya Ray; Yu-Tzu Tai; Yiguo Hu; Ruben D Carrasco; Paul Richardson; Stig Linder; Dharminder Chauhan; Kenneth C Anderson
Journal:  Blood       Date:  2013-12-06       Impact factor: 22.113

3.  Structural basis for the activation and inhibition of the UCH37 deubiquitylase.

Authors:  Ryan T Vander Linden; Casey W Hemmis; Benjamin Schmitt; Ada Ndoja; Frank G Whitby; Howard Robinson; Robert E Cohen; Tingting Yao; Christopher P Hill
Journal:  Mol Cell       Date:  2015-02-19       Impact factor: 17.970

4.  Stabilization of an unusual salt bridge in ubiquitin by the extra C-terminal domain of the proteasome-associated deubiquitinase UCH37 as a mechanism of its exo specificity.

Authors:  Marie E Morrow; Myung-Il Kim; Judith A Ronau; Michael J Sheedlo; Rhiannon R White; Joseph Chaney; Lake N Paul; Markus A Lill; Katerina Artavanis-Tsakonas; Chittaranjan Das
Journal:  Biochemistry       Date:  2013-05-09       Impact factor: 3.162

5.  Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells.

Authors:  Zainab Sabry Othman Ahmed; Xin Li; Feng Li; Hassan Ali Cheaito; Kush Patel; El-Sayed Mohammed Mosallam; Gehad Abd El-Fattah Hassan Elbargeesy; Q Ping Dou
Journal:  J Cell Biochem       Date:  2018-07-17       Impact factor: 4.429

6.  Facile synthesis of native and protease-resistant ubiquitylated peptides.

Authors:  Caroline E Weller; Wei Huang; Champak Chatterjee
Journal:  Chembiochem       Date:  2014-05-18       Impact factor: 3.164

7.  Mechanism of the Rpn13-induced activation of Uch37.

Authors:  Lianying Jiao; Songying Ouyang; Neil Shaw; Gaojie Song; Yingang Feng; Fengfeng Niu; Weicheng Qiu; Hongtao Zhu; Li-Wei Hung; Xiaobing Zuo; V Eleonora Shtykova; Ping Zhu; Yu-Hui Dong; Ruxiang Xu; Zhi-Jie Liu
Journal:  Protein Cell       Date:  2014-04-22       Impact factor: 14.870

8.  A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.

Authors:  Ningning Liu; Chunjiao Liu; Xiaofen Li; Siyan Liao; Wenbin Song; Changshan Yang; Chong Zhao; Hongbiao Huang; Lixia Guan; Peiquan Zhang; Shouting Liu; Xianliang Hua; Xin Chen; Ping Zhou; Xiaoying Lan; Songgang Yi; Shunqing Wang; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Sci Rep       Date:  2014-06-10       Impact factor: 4.379

9.  Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.

Authors:  Ningning Liu; Xiaofen Li; Hongbiao Huang; Chong Zhao; Siyan Liao; Changshan Yang; Shouting Liu; Wenbin Song; Xiaoyu Lu; Xiaoying Lan; Xin Chen; Songgang Yi; Li Xu; Lili Jiang; Canguo Zhao; Xiaoxian Dong; Ping Zhou; Shujue Li; Shunqing Wang; Xianping Shi; Ping Q Dou; Xuejun Wang; Jinbao Liu
Journal:  Oncotarget       Date:  2014-07-30

10.  Conservation and developmental expression of ubiquitin isopeptidases in Schistosoma mansoni.

Authors:  Roberta Verciano Pereira; Helaine Graziele Santos Vieira; Victor Fernandes de Oliveira; Matheus de Souza Gomes; Liana Konovaloff Jannotti Passos; William de Castro Borges; Renata Guerra-Sá
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11-04       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.